The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05931-y ↗At a glance
Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Soo Han Kim and 9 co-authors. Institution: Department of Internal Medicine, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan, 49241, Republic of Korea. Major MEDLINE topics: Adenocarcinoma, Mucinous, Lung Neoplasms. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
PURPOSE: Invasive mucinous adenocarcinoma (IMA) of the lungs is a rare subtype of lung adenocarcinoma with a limited understanding of its prognosis, particularly in advanced stages. This study aimed to assess the prognosis of patients with advanced IMA by focusing on treatment modalities. METHODS: This single-center retrospective study evaluated 33 patients with IMAs diagnosed with advanced-stage disease or disease progression after curative treatment between 2011 and 2021. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). OS and PFS were calculated from the date of the diagnosis of advanced IMA. RESULTS: The study cohort included 13 patients at the initial advanced stage and 20 patients who progressed after curative treatment. Treatment modalities included conventional chemotherapy in 24 patients (72.7%), targeted therapy in seven (21.2%), immunotherapy in 13 (39.4%), and local ablative therapy (LAT) in 13 (39.4%). The median OS was 32 months (95% confidence interval [CI], 2.9-61.0), with LAT significantly associated with improved OS compared to non-LAT treatment (not reached vs. 11.3 months, p = 0.001). However, there was no significant difference in OS based on conventional chemotherapy (p = 0.396), targeted therapy (p = 0.655), or immunotherapy (p = 0.992). In multivariate analysis, LAT remained an independent prognostic factor for OS (hazard ratio, 0.125; 95% CI, 0.026-0.608; p = 0.01). PFS was 8.6 months (95% CI, 3.6-13.7), with no significant differences observed among the treatment modalities. CONCLUSION: Our findings suggest that LAT may provide favorable survival outcomes in patients with advanced IMA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Internal Medicine, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan, 49241, Republic of Korea.
- Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
- Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
- Department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
- Department of Internal Medicine, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan, 49241, Republic of Korea. mihyunkim@pusan.ac.kr.
- Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea. mihyunkim@pusan.ac.kr.
Cite
APA
Kim, S. H., Seong, H., Lee, J., Ahn, H. Y., Cho, J. S., I, H., Kim, Y. D., Lee, M. K., Eom, J. S., & Kim, M. H. (2024). The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05931-y
Vancouver
Kim SH, Seong H, Lee J, Ahn HY, Cho JS, I H, et al. The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05931-y
BibTeX
@article{Kim2024,
author = {Kim, Soo Han and Seong, Hayoung and Lee, Jonggeun and Ahn, Hyo Yeong and Cho, Jeong Su and I, Hoseok and Kim, Yeong Dae and Lee, Min Ki and Eom, Jung Seop and Kim, Mi-Hyun},
title = {The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05931-y}
}
EUVIMED